

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.



CONTACT

040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com

February 9, 2026

To

BSE Limited

Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Press Release - Rectification of typo error

Ref: Our letter dated February 9, 2026

We refer to our Press Release dated February 9, 2026, please note that there was a typographical error in the date mentioned. It should be read as February 9, 2026, instead of February 9, 2025.

You may note that there are no other changes in the disclosures, except the above.

We regret the inconvenience caused in this regard.

This is for your information and records.

Yours sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above



Neuland 9MFY26 Total income at Rs.1264.5 crore; EBITDA at Rs.284 crore

Hyderabad, India, Feb 9, 2026 – Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the nine months ended Dec 31st, 2025.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, *“The revenues this quarter are in line with the outlook we envisaged for the year, however the product mix within businesses as well as increased operating expenses is reflected in subdued EBITDA margins. We continue to see good momentum in the business which is driving our investments with the long-term in view, ensuring Neuland can take advantage of the number of growth opportunities.”*

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added *“We are seeing increasing interest from a wider range of customers interested in our capabilities as a proven commercial NCE drug substance manufacturer as well as an integral partner in the innovation journey. Our investments are leading to more engagements with existing customers while also attracting new customers who are looking for specific niche capabilities.”*

Financial Summary

Particulars (Rs Cr)	Rs. crore				
	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)
Total Income	447.8	401.9	11.4%	516.1	-13.2%
EBITDA	85.0	90.3	-5.9%	156.9	-45.8%
EBITDA Margin	19.0%	22.5%	-350 bps	30.4%	-1140 bps
Exceptional Item*	-	55.8	-	-	-
Profit Before Tax*	54.3	127.5	-57.4%	129.0	-57.9%
PBT Margin	12.1%	31.7%	-1960 bps	25.0%	-1290 bps
Profit After Tax	40.4	101.4	-60.2%	96.5	-58.1%

Q3 FY26 Earnings Call

The company will conduct a one-hour Earnings call at **17:30 hrs. IST on Monday, Feb 9, 2026** where the management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please register on the link below:

[Diamond Pass Registration Link](#)

Please note that the transcript of the conference call will be uploaded on the company website in due course.

About Neuland Laboratories Limited

For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 1000+ Regulatory filings across the US (73 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID & GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001. For more information, visit www.NeulandLabs.com.

If you have any questions or require further information, please feel free to contact

IR Department at Neuland

Tel: +91 40 6761 1600

Email: ir@neulandlabs.com

Ravi Udeshi / Minakshi Machutre

EY IR

Email: ravi.udeshi@in.ey.com / Minakshi.machutre@in.ey.com